1. GDC-0980, having the structure: for use in the treatment of mesothelioma. 2. The use of GDC-0980 having the structure: for the manufacture of a medicament for the treatment of mesothelioma. 3. The use of GDC-0980, having the structure: for the treatment of mesothelioma. 4. A method of treating mesothelioma, comprising administering to a patient with mesothelioma a therapeutically effective amount of GDC-0980, having the structure: 5. The method of claim 4, wherein the patient has malignant pleural mesothelioma. The method of claim 4, wherein the patient has previously been treated with chemotherapy, radiation therapy and / or surgical resection. The method of claim 6, wherein the patient has previously been treated with one or more chemotherapeutic agents selected from pemetrexed, bevacizumab, cisplatin, gemcitabine, vinorelbine, imatinib, dasatinib, erlotinib, sunitinib and sorafenib. The method of claim 4, wherein the GDC-0980 is administered to the patient daily at intervals of three weeks or four weeks. The method according to claim 8, in which after a three-week interval follows a one-week break when the patient is not given GDC-0980.10. The method of claim 4, wherein the GDC-0980 is administered orally. The method of claim 4, wherein the therapeutically effective amount of GDC-0980 is from 1 mg to 100 mg per day per patient body weight. The method of claim 4, wherein the therapeutically effective amount of GDC-0980 is from 10 mg to 50 mg per day, depending on the patient’s body weight. The method of claim 4, further comprising administering a chemotherapeutic agent selected from pemetrexed, bevacizumab, cisplatin, gemcitabine, vinorelbine, imatinib, dasatinib, erlotinib, sunitinib or sorafenib. The method of claim 4, wherein GDC-0980 is formulated with an ingredient,1. GDC-0980, имеющий структуру:для применения для лечения мезотелиомы.2. Применение GDC-0980, имеющего структуру:для получения лекарственного средства для лечения мезотелиомы.3. Применение GDC-0
